This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tolerability of Grazax-R in Children

This study has been completed.
Information provided by:
ALK-Abelló A/S Identifier:
First received: March 1, 2006
Last updated: May 3, 2006
Last verified: May 2006
This trial is performed to assess whether the Grazax-R treatment is safe to use in children aged 5-12 years.

Condition Intervention Phase
Allergy Biological: ALK Grass tablet Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of GRAZAX-R in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)

Further study details as provided by ALK-Abelló A/S:

Primary Outcome Measures:
  • Assessment of safety by recording of adverse events

Estimated Enrollment: 50
Study Start Date: February 2006
Estimated Study Completion Date: April 2006

Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Grass pollen induced rhinoconjunctivitis
  • Boys and girls, 5-12 years of age
  • Positive skin prick test to grass pollen

Exclusion Criteria:

  • Previous treatment with immunotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00298701

Tangstedter Landstrasse 77
Hamburg, Germany, 22415
Sponsors and Collaborators
ALK-Abelló A/S
Study Director: Kim Simonsen, MD ALK-Abelló A/S
  More Information Identifier: NCT00298701     History of Changes
Other Study ID Numbers: GT-11
Study First Received: March 1, 2006
Last Updated: May 3, 2006

Keywords provided by ALK-Abelló A/S:
Allergy processed this record on August 18, 2017